Background：Statins vary in their effectiveness in lowering low－density lipoproteincholesterol（LDL－C）and increasing high－density lipoprotein cholesterol（HDL－C）levels.We documented that the degree of these changes can explain cardiac risk reduction in theCIRCLE Study. To compare efficacy of the most potent statin, pitavastatin, with no statingroup, especially in diabetic patients, we conducted subanalysis of the CIRCLE Study.Methods and Results：The 431 consecutive patients who underwent PCI from 2001 to2008 were retrospectively investigated. Treatment with pitavastatin significantly reducedLDL－C and increased HDL－C compared with no statin. Pitavatatin significantly preventedmajor adverse cardiac events（MACE）compared with no statin in patients with or withoutdiabetes. Multivariate－adjusted analysis revealed that percent changes of both LDL－C andHDL－C independently predicted the incidence of MACE（hazard ratio［HR］：1.14；95％confidence interval［CI］：1.07－1.21, HR：0.88；95％CI：0.80－0.98, in each 10％ change,respectively）.Conclusions：The extent of changes in LDL－C and HDL－C with statin treatment wouldindependently alter the risk of cardiac events. Pitavastatin potently decrease LDL－C andsignificantly increase HDL－C might provide good prognosis in patients after PCI with orwithout diabetes.